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A highly sensitive spectrophotometric method for the analysis of catecholamine drugs; L-dopa and methyldopa, is described. The analysis 
is based on the reaction of drug molecules with vanadium (V) which is reduced to vanadium (IV) and form complex with eriochrome 
cyanine R to give products having maximum absorbance (λmax) at 565 nm. Beer’s law is obeyed in the range 0.028-0.84 and 0.099-0.996 
μg mL-1 for L-dopa and methyldopa, respectively.  The statistical analysis as well as comparison with reported methods demonstrated 
high precision and accuracy of the proposed method. The method was successfully applied in the analysis of pharmaceutical preparations.  
Keywords: L-dopa; methyldopa; vanadium.
INTRODUCTION
Catecholamine drugs are aromatic vic-diols in which either the 3- or 
4- position is unsubstituted and these positions are not sterically blocked. 
These drugs are now widely used to treat several disorders.  L-Dopa, also 
known as levodopa is used as a first-line treatment for Parkinson’s disease, 
usually along with carbidopa or benserazide.1 The drug readily crosses 
the blood brain barrier and is decarboxylated to dopamine in the brain. It 
has also found to ameliorate the conditions in acromegaly.2 Methyldopa 
is an effective antihypertensive agent when given in conjunction with 
a diuretic. It is a prodrug, which is metabolised to an active metabolite, 
α-methylnorepinephrine, which acts as a α2-adrenergic receptor agonist 
in the brainstem
 
to attenuate the output of vasoconstrictor adrenergic 
signals to the peripheral sympathetic nervous system.3
A vast number of methods have been developed for the analysis 
of these compounds. L-Dopa is estimated by LC-MS-MS,4 chemilu-
minescence,5 HPLC-DAD,6 voltametry7 and HPTLC.8 Similarly, me-
thyldopa has been reported to be estimated by NMR9 and HPLC-MS10 
methods. Also, several spectrophotometric methods are reported for 
the determination of these drugs. L-Dopa is estimated by tris(1,10-
phenanthroline),11 p-nitro aniline,12 sulphanilamide,13 sulfanilic acid,14 
4-aminobenzoic acid,15 isoniazid,16 sodium metaperiodate,17 Cu(II)-
neocuproine,18 chloranil,19 potassium ferricyanide,20 and 4-aminoan-
tipyrine.21 Methyldopa is estimated by tris(1,10-phenanthroline),11 
p-nitro aniline,12 sulphanilamide,13 sulfanilic acid,14 4-aminobenzoic 
acid,15 isoniazid,16 polyphenol oxidase22 and barbituric acid.23  
Herein, we have developed a highly sensitive method for the de-
termination of catecholamine drugs based on the complex formation 
between reduced vanadium and eriochrome cyanine R. The method 
is simple, accurate and free from interference by excipients.
EXPERIMENTAL
Apparatus
A Jasco (Model UVIDEC-610 UV-VIS spectrophotometry with 
1-cm matched quartz cuvettes was used for all absorbance measu-
rements.
Materials
Analytical reagent grade chemicals and bidistilled water were 
used throughout the experiment. L-Dopa (LD) and methyldopa (MD) 
were all purchased from Sigma (USA) and used as working solution 
without further treatment. Sodium metavandate was purchased from 
E. Merk (Germany) and eriochrome cyanine R (ECR) was obtained 
from E. Merk (Germany). Stock solutions of each drug containing 
100 μg mL-1 were prepared by dissolving 10 mg of the respective 
drugs in 100 mL of water. The resulting solutions were standardised 
by the reported method.24 The solutions were further diluted quanti-
tatively according to their linearity range. A 50 μg mL-1 solution of 
vanadium was prepared by dissolving 12 mg of sodium metavandate 
in few drops of dilute HCl and diluting the solution to 100 mL with 
water. A 500 μg mL-1 solution of eriochrome cyanine R was prepa-
red by dissolving 50 mg in 100 mL of water. An acetic acid/sodium 
acetate buffer (0.02M) of pH 5.0 was prepared by dissolving suitable 
quantity in water.
Preparation of tablet/capsule sample solution
 Twenty tablets of each drug was weighed, powdered and mixed 
thoroughly. A quantity equivalent to 10 mg of each drug was trans-
ferred to 100 mL volumetric flask. The drugs were dissolved in water, 
shaken well, and made up to the volume with water.  The resultant 
solutions were filtered, further diluted according to their linearity 
range and analysed as described under the analytical procedure. 
Recommended analytical procedure
Accurately measured suitable volume of LD and MD were 
transferred from stock solution to 10 mL volumetric flasks, which 
could be diluted quantitatively to obtain 0.028-0.84 and 0.099-0.993 
μg mL-1, respectively. To each flask containing drugs in the order 
mentioned above, 1.5 mL of vanadium, 1 mL of acetic acid/sodium 
acetate buffer (0.02M) of pH 5.0 and 3 mL of ECR were added. The 
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solutions were swirled and allowed to stand for 45 min. The absor-
bances were measured at 565 nm against the blank containing all the 
reagents mentioned above except drugs.
 
RESULTS AND DISCUSSION
Spectral characteristic
The absorption spectra of the reaction product were measured 
at 565 nm against the blank solutions. The method is based on 
reduction vanadium (V) by the drugs to vanadium (IV), which 
formed complex with ECR. An attempt to form a ternary complex 
by adding cationic surfactant such as CTAB was not successful 
because the violet color so formed was not stable. The reaction 
was carried out at room temperature. The absorption spectra of 
the colored products are shown in Figure 1.
Optimum reaction condition
By varying one and keeping other experimental parameters 
and the amount of drug constant, the effect of vanadium (V), ECR 
and buffer were studied. Maximum colour intensity was obtained 
when 1.5 mL of vanadium, 3.0 mL of ECR were added. The effect 
of buffer was studied using acetic acid/sodium acetate buffer of 
different pH and maximum absorbance was observed at pH 5.0. 
The effect of pH for LD in the reaction is shown in Figure 2. 
The sensitivity was found to be enhanced when the reaction was 
allowed to be complete in 45 min at room temperature. Attempt 
to use other metal ions such as Al+3, Ce+4, Cu+2, Fe+3 and Zn+2 was 
not successful as the blank itself produced colored product. 
Validation of the proposed method
Linearity, detection and quantification limit
Calibration graphs were constructed using standard solutions 
under optimum experimental condition. A linear relationship was 
observed between the absorbance and concentration of drugs from 
0.028-0.84 and 0.099-0.993 μg mL-1, respectively LD and MD, res-
pectively. The molar absorptivity and sandell’s sensitivity for each 
drug were calculated from beer’s law. The ringbom plots demonstrated 
the optimum range of concentration of 0.03-0.84 and 0.11-0.97 μg 
mL-1 for LD and MD, respectively by the proposed method. The 
graph showed a negligible intercept, which was calculated by the 
least-square method’s regression equation: 
 Y = a + bc 
where, Y is the absorbance of solution in a 1 cm cell, a is the in-
tercept, b is the slope, and c is the concentration of the measured 
solution in μg mL-1. The confidence limits for the slope of line of 
regression and the intercept were computed using the relation, b 
± tSb and a ± tSa at 95% confidence level. The limit of detection 
(LOD) and the limit of quantification (LOQ) value were determined 
using the formula 
 LOD or LOQ = K SD/b 
where K = 3 for LOD and 10 for LOQ, SD and b stand for standard 
deviation of the intercept and slope, respectively. The LOD was 6.6 
x 10-3 and 26 x 10-3 μg mL-1. Similarly, LOQ was found to be 0.022 
and 0.087 μg mL-1. The high correlation coefficients indicate the 
excellent linearity. Repeatability and level of precision was tested 
by analyzing 6 replicate samples and was found to be adequate for 
quantification of drugs as shown by their relative standard deviation. 
The optical characteristic is given in Table 1. 
The error (Sc) in the determination of a given concentration of 
drugs was defined by the expression where,
  
Figure 1. Absorbance spectra of LD (0.45 μg mL-1) and MD (0.35 μg mL-1)
Figure 2. Effect of pH in the absorbance of LD at 0.56 μg mL-1
Table 1. Optical characteristics and statistical data of the regression analysis
Parameter LD MD
λmax (nm) 565 565
Beer’s Law range (μg mL-1) 0.028-0.840 0.099-0.996
Ringbom plots (μg mL-1) 0.03-0.84 0.11-0.97
Molar absorptivity (L mol-1 cm-1 x 105) 2.67 1.68
Sandell’s sensitivity (μg/cm2) x 10-3 0.73 1.41
Limit of detection (μg mL-1) x 10-3 6.6 26
Limit of quantification (μg mL-1) 0.022 0.087
Regression Equation(Y= a + bc)a
Slope (b) ± tSbb 0.7807±0.0473 0.824±0.028
Intercept (a) ± tSac 0.0590±0.0205 0.032±0.015
Correlation coefficient (R) 0.9991 0.9993
Relative standard deviationd 0.44 0.78
aY = a + bc, where c is the concentration of the measured solution in μg mL-1 
and Y is the absorbance unit. bConfidence interval for slope at 95% confidence 
limit for 6 degree of freedom. cConfidence interval for intercept at 95% confi-
dence limit 6 degree of freedom. dAverage of 6 determinations (concentrations 
of 0.28 and 0.5 μg mL-1 of pure drugs of LD and MD respectively)
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—y and —x are the average values of the absorbance and concentration, 
respectively, for n standard samples. The graph shows that the error 
is reached minimum when absorbance corresponding to about 0.4 
and 0.52 μg mL-1 of LD and MD, respectively, when the actual ab-
sorbance is equal to the average absorbance. The plots of error, Sc 
vs. concentration of drugs are shown in Figure 3.
Interference studies 
The effect of common excipients used in the pharmaceutical 
preparation were studied by analyzing synthetic sample solutions 
containing the quantity of drugs as mentioned in Table 2 in presence 
of 100 fold more concentration of each excipients. The tolerance limit 
was defined as the concentration which gave an error of ± 3.0% in 
the determination of drugs. The common excipients such as sodium 
chloride, starch, dextrose, lactose, talc, carboxymethyl cellulose, 
magnesium stearate, sucrose, had no effect in the analysis. 
Precision studies
The short term precision (intraday precision) of the drugs were 
evaluated by measuring 5 independent samples at 3 different con-
centration levels (0.14, 0.28, 0.56 μg mL-1 for LD and 0.50, 0.62 
and 0.74 μg mL-1 for MD. Similarly, the assay for daily precision 
(interday precision) at the same concentration level was repeated for 
5 consecutive days (Table 3). The relative standard deviation ranged 
between 0.3-0.6 and 0.5-0.9 for LD and MD, respectively. The values 
of relative standard deviation can be considered to be satisfactory for 
the routine determination of the drugs. 
The available pharmaceutical dosage forms of the investigated 
drugs were analysed by the proposed method. The precision of the 
method was checked by taking 6 replicate measurements. The results 
obtained by the proposed and the reference methods for the dosage 
forms were compared statistically.
Student’s t- value ≤ 2.44 for pharmaceutical samples at the 95% 
confidence limit indicate insignificant difference between the found 
and true contents of the test. Analytical results measured for the same 
pharmaceuticals by the proposed method and reference method were 
compared using F-test. The F-values ≤ 5.05 thus obtained indicate 
insignificant difference in precision between both methods at 95% 
confidence limit. The standard deviation ranged between 0.15-0.20. 
The reliability and accuracy of the proposed method were further 
ascertained through recovery studies using the standard addition 
method by adding different amount of standard drugs to the pre-
analyzed dosage forms such that the cumulative amount after adding 
the drugs did not exceed their linearity range. The mean percentage 
recoveries, relative to the labeled amounts ranged from 99.9±0.14 
to 100.0±0.11 (Table 4).
CONCLUSION
We have proposed a new spectrophotometric method for the 
determination of catecholamine drugs, which is fairly sensitive, 
simple, and economical with reasonable precision and accuracy. The 
optical parameters and statistical comparison justify this method for 
application in routine drug estimation in pure and dosage forms. 
Also, the procedures do not involve any critical reaction conditions 
or tedious sample preparation steps. So, the recommended method is 
well suited for the assay and evaluation of drugs in pharmaceutical 
preparation and can also be considered as a general method for the 
quantification of listed catecholamine drugs.
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Table 2. Recovery of drugs from solution with a 100-fold excess of various 
additives* used as excipients
Recovery (%)a
Excipients LDb MDc
Dextrose 99.4 ± 0.2 99.7 ± 0.3
Lactose 99.7 ± 0.6 99.9 ± 0.3
Starch 99.4 ± 0.4 99.8 ± 0.7
Sucrose 99.4 ± 0.6 99.3 ± 0.4
Carboxymethyl  cellulose 99.4 ± 0.1 99.7 ± 0.8
Talc 99.5 ± 0.3 99.5 ± 0.3
Magnesium Sterate 99.8 ± 0.2 99.5 ± 0.2
Sodium Chloride 100.0 ± 0.5 100.0 ± 0.3
a Mean ± R.S.D n = 3. b Concentration of LD used-  0.28 μg mL-1. c Concentra-
tion of MD used- 0.5 μg mL-1
Table 3.  Intra-day and Inter-day precision data 
Concentration taken 
(μg mL-1)
Intra-day
 Recoverya
Inter-day 
Recoveryb
0.14 0.14 ± 0.6 0.14 ± 0.9
LD 0.28 0.28 ± 0.3 0.28 ± 0.5
0.56 0.56 ± 0.4 0.56 ± 0.7
0.50 0.5  ± 0.7 0.5  ± 0.8
MD 0.62 0.62 ± 0.5 0.62 ± 0.6
0.74 0.74 ± 0.5 0.74 ± 0.8
a
 Mean ± R.S.D n= 5. b Mean ± R. S.D n= 5,  performed over a period of 5 days
Figure 3. Plot of error in the determination of LD and MD
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Table 4. Analysis of drugs in pharmaceutical formulations
Formulation Mass per dosage form 
(mg)
Proposed method 
(mg)a
Reported methods 
(mg)a, c
Recovery 
(%)b
Error 
(%)
Bidopald 500 500.0 ± 0.20
F=1.08
t=1.03
499.9 ± 0.20 (6) 100.0 ± 0.15 0.07
Alphadopae 250 250.1 ± 0.15
F=1.19
t=0.76
250.0 ± 0.20 (6) 100.0 ± 0.11 0.06
Sembrinaf 250 249.9 ± 0.13
F=1.26
t=2.12
250.1 ± 0.14 (6) 99.9 ± 0.14 0.05
a Mean ± S.D n = 6; the t- and F- values obtained after comparison to the reference methods have following theoretical values at 95% confidence limit; t =  2.44 
F= 5.05. b Mean ± R.S.D n = 6 after adding 4 different amounts of pure drugs to a fixed concentration of pre-analysed  pharmaceutical formulations. c Numbers 
inside the bracket indicates reference number of the reported methods. d LD equivalent to 500 mg/tablet (GSK, India). e MD equivalent to 250 mg/ tablet (Merind 
Ltd, India). f MD equivalent to 10 mg/tablet (Aventis, India) 
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